FindTrial
Sign In

Sacituzumab Tirumotecan (SKB264) plus Tislelizumab

DRUG2 trials

Sponsors

Zhejiang Provincial People's Hospital, Shanghai Chest Hospital

Conditions

Advanced Thyroid CarcinomaEsophageal Squamous Cell CarcinomaPoorly Differentiated Thyroid CarcinomaRadioiodine-refractory Differentiated Thyroid Cancer

Phase 2

Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
RecruitingNCT07811752
Shanghai Chest HospitalEsophageal Squamous Cell Carcinoma
Start: 2026-07-30End: 2028-12-31Target: 28Updated: 2026-09-10

Unknown Phase

Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
RecruitingNCT07068542
Zhejiang Provincial People's HospitalAdvanced Thyroid Carcinoma, Poorly Differentiated Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer
Start: 2025-07-01End: 2028-12-31Target: 94Updated: 2026-06-01